Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy.


Immunotherapy utilizing the adoptive transfer of lymphokine activated killer (LAK) cells in conjunction with recombinant interleukin 2 (RIL-2) is capable of reducing established metastatic cancer in a variety of animal tumor models. A major difficulty in the application of these efforts to the treatment of human cancer has been the activation in vitro of up… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.